Skip to content

Nuvation Bio NUVB Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Pfizer logo
PfizerPFE
7.8%+4.6pp
Immunome logo
ImmunomeIMNM
-8.3%-3.4pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-18.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-17.7%-3.8pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-3%-1.4pp

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Based on trailing twelve months.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's free cash flow yield?
Nuvation Bio (NUVB) reported free cash flow yield of -9% in Q1 2026.
How has Nuvation Bio's free cash flow yield changed year-over-year?
Nuvation Bio's free cash flow yield increased by 66.0% year-over-year, from -26.4% to -9%.
What is the long-term trend for Nuvation Bio's free cash flow yield?
Over 5 years (2020 to 2025), Nuvation Bio's free cash flow yield has grown at a 26.2% compound annual growth rate (CAGR), from -1.8% to -5.9%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.